Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multimodal analgesia with nalbuphine and flurbiprofen axetil after laparoscopic hepatectomy
ChiCTR2100044538Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of nalbuphine, pentazocine and flurbiprofen axetil in hepatocellular carcinoma (HCC) and postoperative pain (5 arms), sponsored by Tongji Hospital. Primary endpoints: VAS pain score and Postoperative adverse reactions (PONV). Started Apr 2021; status: recruiting.
02
Drugs
nalbuphinepentazocineflurbiprofen axetil
03
Conditions
hepatocellular carcinoma (HCC)postoperative pain
Beyond the preview
Go deeper on ChiCTR2100044538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044538.